Press Release

Ref: ISLL:CH:2026 Date: 30th October, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB Sub.: Press Release in respect of Unaudited Financial Results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2026 Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release regarding the Company's financial results for the quarter ended September 30, 2026. You are kindly requested to take the above information on record. Thanking you, For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Encl: a/a Ind-Swift Laboratories Q2 FY27: Revenue up 50%, Op. EBITDA Surges 5.2x, PAT up 3.5x, EBITDA Margin Expands 1,279 BPS Chandigarh, October 30th, 2026 - Ind-Swift Laboratories Limited (BSE: 532305 | NSE: INDSWFTLAB), a leading pharmaceutical formulations company with a presence across 85+ countries, announced its unaudited financial results for Q2 and H1 FY27, delivering a sharp step-up in revenue, profitability and margins. The performance is led by the Company's earlier transition from an API manufacturer to a Finished Dosage Formulations (FDF) manufacturer and the further scale-up of its operations. The Company's CDMO partnerships have started to pick up and are now contributing much better to the topline, while the shift in business mix has lifted margins. Operating efficiency improved alongside growth. Raw material expense fell to 45.15% of revenue from 49.38% in Q2 FY26. Growth was driven by core operations: non- operating other income declined 35.95% to ₹7.60 crore, yet PBT rose 3.6x to ₹40.24 crore. Finance cost declined 33.83% to ₹1.33 crore. Sequentially, revenue grew 26.23% and Op. EBITDA grew 27.02% over Q1 FY27 (₹186.08 crore and ₹33.32 crore respectively), with Op. EBITDA margin improving from 17.91% to 18.02%. For H1 FY27, revenue rose 35.79% to ₹420.97 crore, Op. EBITDA rose 4.4x to ₹75.65 crore at a margin of 17.97%, and PAT rose 3.3x to ₹55.47 crore. Standalone Key Financial Highlights – Q2FY27: Particulars (₹ Crs.) Q2 FY27 Q2 FY26 Y-o-Y Change (%) Operating Income 234.89 156.43 50.15 Op. EBITDA 42.33 8.55 4.95x Op. EBITDA (%) 18.02 5.46 1256.01 BPS PAT 31.03 8.76 3.54x PAT Margin (%) 13.21 5.60 761.18 BPS Standalone Key Financial Highlights - H1 FY27: Particulars (₹ Crs.) H1 FY27 H1 FY26 Y-o-Y Change (%) Operating Income 420.97 310.02 35.79 Op. EBITDA 75.65 16.98 4.45x Op. EBITDA (%) 17.97 5.47 1253.66 BPS PAT 55.47 16.88 3.29x PAT Margin (%) 13.18 5.44 773.35 BPS Management Commentary Mr. N.R. Munjal, Chairman of Ind-Swift Laboratories, further stated, “Q2 FY27 is a strong validation of the strategic choices we made earlier. Our transition from an API manufacturer to a Finished Dosage Formulations (FDF) manufacturer and the scale-up of our operations on that platform is now clearly visible in the numbers. Revenue grew 50.15% to ₹234.89 crore, operating EBITDA rose 5.1x to ₹42.33 crore and operating EBITDA margin expanded by 1,279 bps to 18.02%, while PAT rose 3.5x to ₹31.03 crore, with PAT margin at 13.21%. The shift to FDF has improved our business mix and lifted margins, and the scale- up of operations is delivering operating leverage. Raw material expense fell to 45.15% of revenue from 49.38% a year ago, a 423 bps. Growth has come from core operations, with PBT rising 3.6x to ₹40.24 crore even as non-operating other income declined. With a net-debt-free balance sheet, a focused FDF platform and a stronger operating base, we remain committed to scaling operations further and sustaining profitable growth.” About Ind-Swift Laboratories Limited Ind-Swift Laboratories Limited is a global pharmaceutical company focused on finished dosage formulations, serving regulated and emerging markets through a diversified model spanning international exports, domestic branded formulations, and contract development & manufacturing partnerships. Company operates manufacturing facilities with multiple international regulatory accreditations and is supported by a dedicated formulation R&D infrastructure, enabling product development, filings, and commercialization across key therapeutic segments and geographies. Post its strategic restructuring and API & CRAMS divestment, Ind-Swift operates as a net-debt-free, pure-play formulations platform with a strong, capital-efficient balance sheet. Backed by a robust dossier pipeline, established partnerships, and broad international presence, the Company is focused on expanding exports, strengthening CDMO visibility, and delivering sustainable growth with improving margins. Disclaimer This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances. For further Info Please contact Pardeep Verma Investor Relations Advisors VP-Corporate Affairs and Company Confideleap Partners Secretary info@confideleap.com +91-9814131627 +(91) 85911 45959 investor@indswiftlabs.Com www.confideleap.com